Evidence map›Paper›PMID 35602932›Full record

ArticleLeukemia research reports2022

Peripheral blood CD26 positive leukemic stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia.

Huda F Ebian, Al-Shabrawy M Abdelnabi, Abdallah S Abdelazem, Tarek Khamis, Hebatallah M Fawzy, Samia Hussein

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05543161 ("Peripheral Blood Dipeptidylpeptidase IV), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05543161 unknown statusnot on this map

"Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker"

TypeobservationalSponsorSohag UniversityRan2022 to 2023Enrolled50ConditionsChronic Myeloid Leukemia, Chronic Phase
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Huda F EbianClinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Al-Shabrawy M AbdelnabiInternal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Abdallah S AbdelazemMedical Biochemistry Department, Faculty of Medicine, Suez University, Suez, Egypt.
Tarek KhamisPharmacology Department, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.
Hebatallah M FawzyPublic Health and Community Medicine Department, Faculty of Medicine, Zagazig University Zagazig, Egypt.
Samia HusseinMedical Biochemistry& Molecular Biology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Zagazig University · EGSuez University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: CD26 is expressed in all chronic myeloid leukemia (CML) patients. This study investigated the role of CD26 Method: Flow cytometry was performed to evaluate CD26 Results: CD26 Conclusion: CD26+ LSCs can be a useful marker in diagnosis and follow up of patients with CML.

Indexed as

CD26CP-CMLLSCsTKI

Identifiers

PMID35602932
PMCPMC9118510
OpenAlexW4225371230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.